

Energy | Company Research

Bringing China to the World


30 March 2015

增持

维持

Market Data: Mar.27 Closing Price (HK\$) 10.50 Price Target (HK\$) 12.65 HSCEL 11.920 HSCCI 4,515 52-week High/Low (HK\$) 15.88/9.72 Market Cap (USD Mn) 59,774 Market Cap (HK\$ Mn) 463.441 Shares Outstanding (Mn) 44,647 Exchange Rate (RMB-HK\$) 1.26

Price Performance Chart:



Source: Bloombera

Analyst

Albert Miao A0230513050007 **BDE609**

miaohx@swsresearch.com

Contact

Albert Miao (8621)23297818×7238

Related Reports

"CNOOC (883 HK): Sea change" Feb 6, 2015

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page

中海油(883:HK)

Financial summary and valuation								
	2013	2014	2015E	2016E	2017E			
Revenue (Rmbm)	285,857.00	274,634.00	215,317.23	254,014.94	260,533.82			
YOY (%)	15.44	(3.93)	(21.60)	17.97	2.57			
Net income (Rmbm)	56,461.01	60,199.01	22,995.39	53,591.79	58,016.25			
YOY (%)	(11.35)	6.62	(61.92)	133.05	8.26			
EPS (Rmb)	1.26	1.35	0.51	1.20	1.30			
Diluted EPS (Rmb)	1.26	1.35	0.51	1.20	1.30			
ROE (%)	16.53	15.86	5.79	13.70	13.53			
Debt/asset (%)	45.03	42.73	44.58	45.66	43.03			
Dividend yield (%)	5.41	5.42	1.85	4.32	5.46			
PE (x)	6.59	6.18	16.18	6.94	6.41			
PB (x)	1.09	0.98	1.05	0.95	0.87			
EV/Ebitda (x)	3.73	3.62	4.98	3.51	3.39			

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised.

远不止业绩超预期, 中海油 2014 年录得净利润人民币 602 亿元(每股盈利人民币 1, 35 元). 相比 2013 年同比增长 6.6%, 较我们预期的净利润人民币 543 亿元(每股盈利人民币 1.22 元) 高出 11%, 较市场一致预期的净利润人民币 517 亿元(每股盈利人民币 1.16 元) 高出 16%,主要因为公司超预期的成本控制。此外,我们认为 2015 中海油将在公司治理上得到 显著提升,在改革浪潮中最为成功,主要来自于1)公司在多年业绩低于指引或预期之后 2014 年业绩超预期,2)强有力的成本控制展现了公司执行力的显著提高和 3)公司更给 出了一个非常清晰的长期战略来应对低油价环境。

股息超预期。管理层建议派发每股0.32港元(含稅)的末期股息,相当于33.5%的分红率 (14 年上半年则为 26.4%), 而股息收益率则为 5.4%。这将消除市场对于在恶劣的市场环 境中股息削减的担忧。我们认为好于预期的股息主要得益于审慎的财务政策以及健康的资 产负债表(2014 年和 2013 年有息负债率分别为 26.5%和 27.8%)。

成本控制。作为中国石油公司中第一个作业费用同比下降的公司,中海油好于预期的成本 控制将会重塑公司的形象。2014年是中海油的"质量和效率"之年,所有项目都按照严格 的质量管理来运行, 其中大部分项目都提前进入进入商业运行并低于预算, 同时实现了超 过 10%的操作成本节省和 10%的效率提升,从而使公司总费用从 2013 年的高点迎来 2014 年的首次下降,总费用下降了 2.5 美元/桶至 42.3 美元/桶。其中,作业费用,勘探费用 和销售及行政管理费用分别下降了 0.03, 2.4, 0.62 美元/桶。

维持增持评级。我们维持 2015 年每股盈利预测为人民币 0.51 元(同比下降 61.9%), 2016 年每股盈利预测为人民币 1.2 元(同比增长 133.1%),并预测 2017 年每股盈利为人民币 1.3 元(同比增长 8.3%)。我们维持目标价港币 12.65 元,对应 15 年 19.3x PE, 16 年 8. 4x PE, 以及 17 年 7. 7x PE。基于仍有 19%的上行空间,我们维持增持评级。在行业中 我们依旧首选中海油,基于公司治理能力显著改善,成本优势,以及在行业中相对便宜的 估值。

Investment highlights:

Far more than earnings beat. CNOOC reported 2014 net profit of Rmb60.2bn and EPS of Rmb1.35 (+6.6% YoY), 11% higher than our expectation of Rmb54.3bn or EPS of Rmb1.22, 16% higher than consensus forecasts of Rmb51.7bn and EPS of Rmb1.16, mainly due to better than expected cost controls. The results underscore our view that the company stands out in the sector as making genuine changes after years of guidance and consensus forecast misses and better cost controls. We see this as a signal of significantly improved execution and a clearer than ever long-term strategy that is well-prepared for low oil price environment, and expect significant improvements in corporate governance in 2015.

Dividends beat. Management proposed a year-end dividend of HK\$0.32/share (tax inclusive), which indicates a dividend payout ratio of 33.5% (1H14: 26.4%) and a dividend yield of 5.4%. This will eliminate market concerns of dividend cut amid tough market environment. We think this better-than-expected dividend is a result of prudent financial policy adopted by the company and its healthy balance sheet (gearing: 26.5% in 2014 and 27.8% in 2013).

Cost controls. With CNOOC being the first oil company in China to report a YoY fall in lifting cost in addition to an earnings beat, we believe the unexpectedly effective cost controls will help reshape the company's image. In 2014, all projects were conducted with stringent quality control, most of which came on-stream ahead of schedule and below budget, and achieved over 10% operating expenses savings and 10% efficiency improvement, leading to a peak in all-in cost in 2013 and the first fall by US\$2.5/boe to US\$42.3/boe in 2014. Notably, lifting costs fell by US\$0.03/boe, exploration cost fell US\$2.4/boe and SG&A expenses fell US\$0.62/boe.

Maintain Outperform. We maintain our EPS forecast of Rmb0.51 (-61.9% YoY) in 15E and Rmb1.2 (+133.1% YoY) in 16E, and forecast 17E EPS of Rmb1.3 (+8.3% YoY). We maintain our target price of HK\$12.65, representing 19.3x 15E PE, 8.4x 16E PE and 7.7x 17E PE. With 19% upside, we maintain our Outperform rating, and CNOOC as our top pick in the sector given its likely improvements in corporate governance, cost competiveness and cheaper valuation among peers.

Fig 1: Company's income statements of 2014A vs 2014E

Mn RMB	2012A	2013A	2014A	YoY	2014E	2014A VS 2014E
Revenue	247,627	285,857	274,634	-3.9%	276,903	-2,269
Oil and gas sales	194,774	226,445	218,210	-3.6%	222,903	-4,693
Marketing revenues	50,771	55,495	50,263	-9.4%	50,000	263
Other income	2,082	3,917	6,161	57.3%	4,000	2,161
Expense	-160,486	-207,354	-193,719	-6.6%	-199,019	5,300
Operating expenses	-21,445	-30,014	-31,180	3.9%	-28,963	-2,217
Production taxes	-15,632	-15,937	-11,842	-25.7%	-15,603	3,761
Exploration expenses	-9,043	-17,120	-11,525	-32.7%	-16,660	5,135
DD&A	-32,903	-56,456	-58,286	3.2%	-59,217	931
Special oil gain levy	-26,293	-23,421	-19,072	-18.6%	-21,653	2,581
Impairment and provision	-31	45	-4,120	-9255.6%	0	-4,120
Crude oil and product purchases	-50,532	-53,386	-47,912	-10.3%	-49,000	1,088
SG&A	-3,377	-7,859	-6,613	-15.9%	-6,923	310
Others	-1,230	-3,206	-3,169	-1.2%	-1,000	-2,169
Operating Profit	87,141	78,503	80,915	3.1%	77,885	3,030
Interest income	1,002	1,092	1,073	-1.7%	389	684
Finance costs	-1,603	-3,457	-4,774	38.1%	-4,054	-720
Exchange gains, net	359	873	1,049	20.2%	0	1,049
Investment income	2,392	2,611	2,684	2.8%	2,000	684
Share of profits of associates	284	133	232	74.4%	234	-2
Share of profits of joint ventures	-311	762	774	1.6%	779	-5
Non-operating income/(expenses), net	908	334	560	67.7%	300	260
Profit before taxation	90,172	80,851	82,513	2.1%	77,532	4,981
Income tax expense	-26,481	-24,390	-22,314	-8.5%	-23,260	946
Profit for the year	63,691	56,461	60,199	6.6%	54,272	5,927

Source: Company data, SWS Research

APPENDIX

Consolidated Income Statement

Rmb Mn	2013	2014	2015E	2016E	2017E
Revenue	285857	274634	215317	254015	260534
Oil and gas sales	226445	218210	161317	200015	206534
Marketing revenues	55495	50263	50000	50000	50000
Other income	3917	6161	4000	4000	4000
Expense	207354	193719	180917	175903	176559
Operating expenses	30014	31180	30024	29358	29597
Production taxes	15937	11842	18000	14001	14457
Exploration expenses	17120	11525	10238	9450	9450
DD&A	56456	58286	66842	65360	64573
Special oil gain levy	23421	19072	0	2654	3532
Impairment and provision	-45	4120	0	0	0
Crude oil and product purchases	53386	47912	49000	49000	49000
SG&A	7859	6613	5814	5080	4950
Others	3206	3169	1000	1000	1000
EBITDA	134959	139201	101242	143471	148548
EBIT	78503	80915	34400	78112	83974
Finance Costs	1119	32	-2402	-2868	-2486
Profit before tax	80851	82513	32745	76560	82880
Income tax expense	24390	22314	9824	22968	24864
Minority interests	0	0	0	0	0
Profit for the year	56461	60199	22922	53592	58016

Source: SWS Research

Consolidated Cash Flow Statement

Rmb Mn	2013	2014	2015E	2016E	2017E
Profit before taxation	80851	82513	32745	76560	82880
Plus: Depr. and amortisation	56456	58286	66842	65360	64573
Finance cost	1492	2652	4402	4868	4486
Losses from investments	-3551	430	-2447	-3015	-3092
Change in working capital	3558	14726	-2453	-9864	1882
Others	-24357	-2329	-12276	-32832	-22982
CF from operating activities	110891	141552	89266	110940	125866
CAPEX	-86717	-53928	- 153022	-56340	-36684
Other CF from investing activities	-83315	-3369	667	-19618	-59186
CF from investing activities	- 170032	-57297	- 152355	-75958	-95870
Equity financing	0	0	0	0	0
Net change in liabilities	42656	4711	3437	0	-10000
Dividend and interest paid	-24058	-24941	-11601	-21328	-25381
Other CF from financing activities	3	0	0	0	0
CF from financing activities	18601	-20230	-8164	-21328	-35381
FCFF	27410	77685	-64056	54299	88881
FCFE	68574	79744	-65021	49432	74396

Source: SWS Research



Consolidated Balance Sheet

Rmb Mn	2013	2014	2015E	2016E	2017E
Current Assets	146552	140708	70095	81464	84151
Bank balances and cash	40536	37753	22369	25128	29533
Trade and other receivables	34136	29441	26886	33336	34422
Inventories	9153	10608	4840	6000	6196
Other current assets	62727	62906	16000	17000	14000
Long-term investment	31195	30587	23284	23000	23000
PP&E	419102	463222	603507	633682	665366
Intangible and other assets	24624	28342	17000	17000	17000
Total Assets	621473	662859	713886	755146	790437
Current Liabilities	128948	103498	110229	108976	109140
Borrowings	49841	31180	20000	20000	20000
Trade and other payables	48558	52192	45229	43976	44140
Other current liabilities	30549	20126	45000	45000	45000
Long-term liabilities	150905	179751	208000	213000	208000
Total Liabilities	279853	283249	318229	321976	317140
Minority Interests	0	0	0	0	0
Shareholder Equity	341620	379610	395656	433170	473297
Share Capital	949	43081	949	949	949
Reserves	340671	336529	394707	432221	472347
Equity attributable	341620	379610	395656	433170	473297
Total Liabilities and equity	621473	662859	713885	755146	790436

Source: SWS Research

Key Financial Ratios

Rmb Mn	2013	2014	2015E	2016E	2017E
Ratios per share (yuan)					
Earnings per share	1.26	1.35	0.51	1.20	1.30
Diluted EPS	1.26	1.35	0.51	1.20	1.30
Operating CF per share	2.48	3.17	2.31	2.48	2.82
Dividend per share	0.45	0.45	0.15	0.36	0.45
Net assets per share	7.65	8.50	8.86	9.70	10.60
Key Operating Ratios(%)					
ROIC	14.45	14.72	6.21	13.19	12.97
ROE	16.53	15.86	5.79	12.37	12.26
EBITDA Margin	47.21	50.69	47.02	56.48	57.02
EBIT Margin	27.46	29.46	15.98	30.75	32.23
Growth rate of Revenue(YoY)	15.44	-3.93	-21.60	17.97	2.57
Growth rate of Profit(YoY)	-11.35	6.62	-61.92	133.80	8.26
Debt-to-asset ratio	45.03	42.73	44.58	42.64	40.12
Turnover rate of net assets	83.68	72.35	54.42	58.64	55.05
Turnover rate of total assets	46.00	41.43	30.16	33.64	32.96
Effective tax rate (%)	30.17	27.04	30.00	30.00	30.00
Dividend yield (%)	5.41	5.42	1.85	4.32	5.46
Valuation Ratios (X)					
P/E	6.59	6.18	16.23	6.94	6.41
P/B	1.09	0.98	0.94	0.86	0.79
EV/Sale	1.76	1.83	2.34	1.98	1.93
EV/EBITDA	3.73	3.62	4.98	3.51	3.39

Source: SWS Research

Information Disclosure:

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of Shenwan Hongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for the relevant disclosure materials or log into www.swsresearch.com for the analysts' qualifications, the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating:

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

 $Trading \ BUY: Share \ price \ performance \ is \ expected \ to \ generate \ more \ than \ 20\% \ upside \ over \ a \ 6-month \ period.$

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

 $Hold: Share\ price\ performance\ is\ expected\ to\ generate\ between\ 10\%\ downside\ to\ 10\%\ upside\ over\ a\ 12-month\ period.$

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period.

Industry Investment Rating:

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

 $Overweight: Industry\ performs\ better\ than\ that\ of\ the\ whole\ market\ ;$

Equal weight: Industry performs about the same as that of the whole market;

Underweight: Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

Disclaimer:

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (http://www.swsresearch.com). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment.

Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies.

This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of Shenwan Hongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Important US Regulatory Disclosures on Subject Companies

This material was produced by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or an authorized affiliate of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities). This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates consider to be reliable. None of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

- 1. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
- 2. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more person of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
- 5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.
- 6. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

Distribution in Singapore

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.